1315 related articles for article (PubMed ID: 16279899)
1. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
3. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
6. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
7. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
Malone DC; Tran TT; Poordad FF
J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
[TBL] [Abstract][Full Text] [Related]
9. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
10. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
11. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
12. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
[TBL] [Abstract][Full Text] [Related]
14. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
15. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
Jacobson IM; Gonzalez SA; Ahmed F; Lebovics E; Min AD; Bodenheimer HC; Esposito SP; Brown RS; Bräu N; Klion FM; Tobias H; Bini EJ; Brodsky N; Cerulli MA; Aytaman A; Gardner PW; Geders JM; Spivack JE; Rahmin MG; Berman DH; Ehrlich J; Russo MW; Chait M; Rovner D; Edlin BR
Am J Gastroenterol; 2005 Nov; 100(11):2453-62. PubMed ID: 16279900
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
Roffi L; Colloredo G; Pioltelli P; Bellati G; Pozzpi M; Parravicini P; Bellia V; Del Poggio P; Fornaciari G; Ceriani R; Ramella G; Corradi C; Rossini A; Bruno S;
Antivir Ther; 2008; 13(5):663-73. PubMed ID: 18771050
[TBL] [Abstract][Full Text] [Related]
18. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
Roomer R; Bergmann JF; Boonstra A; Hansen BE; Haagmans BL; Kwadijk-de Gijsel S; van Vuuren AJ; de Knegt RJ; Janssen HL
Antivir Ther; 2012; 17(3):509-17. PubMed ID: 22300892
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]